Table 3 Triptan-related adverse events
DFN-11 (n = 111) n (%) | Placebo (n = 119) n (%) | Total (N = 230) n (%) | |
|---|---|---|---|
Subjects with ≥1 triptan-related AE | 8 (7.2) | 3 (2.5) | 11 (4.8) |
Palpitations | 0 (0.0) | 1 (0.8) | 1 (0.4) |
Nausea | 2 (1.8) | 0 (0.0) | 2 (0.9) |
Chest discomfort | 1 (0.9) | 2 (1.7) | 3 (1.3) |
Dizziness | 1 (0.9) | 0 (0.0) | 1 (0.4) |
Lethargy | 1 (0.9) | 0 (0.0) | 1 (0.4) |
Paresthesia | 3 (2.7) | 0 (0.0) | 3 (1.3) |
Dyspnea | 0 (0.0) | 1 (0.8) | 1 (0.4) |
Throat irritation | 1 (0.9) | 0 (0.0) | 1 (0.4) |
Throat tightness | 2 (1.8) | 0 (0.0) | 2 (0.9) |